
Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma
About this episode
Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice.
Presenters:
Sagar Lonial, MD, FACP, FASCO
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Mohamad Mohty, MD, PhD
Sorbonne University
Paris, France
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Visit the program page for more content associated with this discussion.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Decera Clinical Education Oncology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Decera Clinical Education Oncology Podcast

Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers,...
Decera Clinical Education Oncology Podcast

ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer
Decera Clinical Education Oncology Podcast

CELMoDs on the Horizon: A New Chapter in Lymphoma Care
Decera Clinical Education Oncology Podcast

Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Mye...
Decera Clinical Education Oncology Podcast